Microglial activation is related to tau pathology and cognitive decline in symptomatic patients [137–139] but might be more closely related to Aβ burden in the absence of cognitive symptoms [140], an effect that could be modulated by the APOE4 genotype [141]. This evidence concerns the gene MAPT and Mental deterioration.